CareTrust REIT, Inc. 8-K

What Happened

• CareTrust REIT, Inc. (CTRE) announced a follow-on public offering that closed on May 20, 2026. The company and its operating partnership entered into underwriting and forward sale agreements with Wells Fargo Securities LLC and J.P. Morgan Securities LLC (underwriters/forward sellers) and Wells Fargo Bank, N.A. and JPMorgan Chase Bank, N.A. (forward purchasers).
• The offering consisted of 12,500,000 firm shares of common stock at $40.225 per share (initial forward sale price), representing gross proceeds of approximately $502.8 million before underwriting discounts and expenses. The underwriters have a 30-day option to purchase up to 1,875,000 additional shares.

Key Details

• Firm shares sold: 12,500,000; Price to underwriters: $40.225 per share; closing date: May 20, 2026.
• Potential additional (over-allotment) shares: 1,875,000 (option exercisable within 30 days) — if exercised, adds ~ $75.4M in gross proceeds.
• Forward structure: forward sale agreements dated May 18, 2026; forward sellers borrowed and sold the firm shares on May 20, 2026. Physical settlement of the forwards may occur on one or more dates up to May 20, 2027; the company may also elect cash or net-share settlement under certain conditions.
• Offering made under the company’s Form S-3 shelf (filed Feb 17, 2026) and prospectus supplement dated May 18, 2026; DLA Piper provided a Maryland law opinion filed as an exhibit.

Why It Matters

• The offering raises substantial capital (approximately $502.8M now, up to ~$578.2M if the option is exercised) which changes the company’s share count and capital position. For existing shareholders, issuance of new shares is dilutive to ownership percentages.
• The forward-sale structure means settlement may be delayed (through May 20, 2027) and could be settled in cash or shares, which affects the ultimate timing and form of dilution and cash received by the company.
• Investors should monitor CTRE’s disclosures for how the company intends to use the net proceeds and whether the underwriters’ option is exercised, as both affect future share count and capital strategy.